‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒ ‒ Financing Completed in December 2019 Funds Company into the Second Quarter of 2021 ‒ ‒ Company to Host Conference Call and

BOSTON and JERUSALEM, March 16, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report financial and business results for the quarter and year ended December 31, 2019, on March 26, 2020, before

BOSTON and JERUSALEM, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering (the “Offering”) with a

BOSTON and JERUSALEM, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (the “Company” or “Entera”), a global innovator in drug delivery platforms, announced today it has closed a private placement offering  (the “Offering”) with a select group of accredited investors, including

BOSTON and JERUSALEM , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and

Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020 Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients. Conference call and live webcast today at 8:30 am Eastern Time BOSTON and JERUSALEM, Nov.

Conference Call Scheduled for 8:30am ET / 3:30pm IST BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S.

  Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting   Data suggest favorable pharmacologic and pharmacokinetic profiles of Entera’s Oral PTH formulation with a flexible oral

JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern

Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019. Appointed Adam Gridley as Chief Executive Officer Conference call and live webcast